Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-Arm, Phase II Clinical Trial of QLS4131 for the Treatment of Relapsed/Refractory Multiple Myeloma With Extramedullary Disease

NCT07903636 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT07903636 Not yet recruiting Phase 2 55 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07903636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started December 2026. Interventional study, Phase 2, 55 participants (estimated). Lead sponsor Institute of Hematology & Blood Diseases Hospital, China; China. Primary measure: Overall Response Rate (ORR).

How it compares

1,104 similar trials: same condition (Multiple Myeloma) and phase

Enrollment

This trial
55
Middle half
18 to 73
Median
40
Trials with a value
1,062

Months from start to completion

This trial
24
Middle half
35.3 to 89.1
Median
57
Trials with a value
1,047

Sites

This trial
1
Middle half
1 to 7
Median
1
Trials with a value
1,049
Posted results or a linked paper 56% 613 of 1,104 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-Arm, Phase II Clinical Trial of QLS4131 for the Treatment of Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 1, 2028
Enrollment
55 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Multiple Myeloma

Registry terms: multiple myeloma (mm)

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
China
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China

Arms

As registered; 1 arm.

Registered arms
Arm Type Interventions
QLS4131 Experimental QLS4131
Show registry wording

Participants will receive QLS4131 12 mg by subcutaneous injection. Step-up doses of 0.6 mg and 3 mg will be administered before the first full dose. QLS4131 will be given every 2 weeks during Cycle 1 and every 4 weeks thereafter. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, investigator decision, or completion of 24 cycles.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Overall Response Rate (ORR) From the first dose to the end of Cycle 24 (each cycle is 28 days).

Lead sponsor's other trials

Institute of Hematology & Blood Diseases Hospital, China, most recent start first.

Similar trials

Same condition (Multiple Myeloma) and phase, most recent start first.